To assess the contnbution of mhented antithrombin deticiency to mortdhty, we mvestigated the causes of death in 14 famtlies wtth inhertted antithrombm deficiency Between 1830 and 1994, 86 of 266 fami ly members who had a probabthty of 0 5 or more for heterozygosity died The causes of death were obtained for 58 ot 66 deaths occumng between 1940 and 1994 Standardtzed moitahty ratios (SMR) were calculated ustng mortahty rates from the general populatton adjusted for age, sex and calendar peitod
Introduction
Inherited antithrombin deficiency is an uncommon autosomal disordei associated with a tendency to venous thromboembolism In famihes with mhented antithiombm deficiency, (recurrent) thromboembohc episodes manifest in heterozygous members, with the tirst thiombosts usually occurrmg between 20-40 years of age (l) These episodes mostly consist of venous thrombosis of the lower extremities and pulmonary embohsm, though sometimes thrombosis occurs at unusual Sites such äs cerebral and mesentenc vems These latter mamfestations äs well äs Correspondente to Dr F R Rosendaal, Department of Clinical Epidemiol ogy, University Hospital, Buildmg l CO-P45, P 0 Box 9600,2300 RC Leiden. The Netherlands -Tel +3171 5264037, FAX Number +3171 5248122 pulmonary embohsm can become hfe-threatenmg events and have been reported äs fatal thiomboembohc complications in some famihes (2) We have already reported a study of overall mortahty m 10 famihes with mhented antithrombm deficiency (3) It was found that mhented antithrombin deficiency did not appear to affect survival äs compared with the general population Similarly, we found a normal hfe expectancy m famihes with another mhented nsk factor for thrombosis, i e protem C deficiency (4) Thus. although these genetic disorders mciease the nsk of thrombosis, it was concluded that they do not mcrease overall mortahty
Although antithrombm deticiency may not lead to a noticeable number of excess deaths, it may still mcrease specific mortahty ansing from one or more causes It is conceivable that the overall mortahty figures mask an mcreased number of deaths due to venous thrombosis We have therefore in the present study analyzed the causes of death in 14 Dutch famihes with mhented antithrombm deficiency with particular emphasis on causes related to thrombosis We compared the pattern of mortahty to that expected in the general population in order to assess to what extent mhented antithrombm deficiency contnbutes to mortality
The use of oral anticoagulation will prevent many thrombotic events, nonfatal and fatal Current guidelmes for mdividuals with antithrombin deficiency are not uniform, especially with regard to longterm anticoagulant prophylaxis m asymptomatic mdividuals This issue is important, smce long-term anticoagulant treatment is also associated with a nsk of disabihty and death from cerebral hemorrhages and other major hemorrhages (5,6) So, there may even be an excess of deaths of venous thromboembohc diseases in antithrombm deficiency that is not outweighed by the nsk of anticoagulant prophylaxis
Methods
Famdies Fourteen Dutch famihes with mhented antithrombm deficiency participated m this study The diagnosis was mitially based on antithrombin activity levels of less than 80% of normal, but smce then many underlymg genetic defects have been identified (7) In 2 famihes a hepann bmdmg defect was found and m 9, a defect underlymg type I antithrombm deficiency In 3 famihes with type I deficiency phenotype, a defect has not yet been identified
We used municipal population records and state archives to complete the pedigrees and to obtam Information on date of birth, date of death and the death certificates We restnüed our study population to those who were deficient with certamty and those who had a Mendehan probability of 0 5 of camership of the defect These genetic probabihties greater than or equal to 0 5 could be assigned m the pedigrees followmg Mendehan rules smce antithrombm deficiency is a dominant autosomal disorder with a low rate of new mutations All first degree family members of camers were assigned a probability of 0 5, regardless of the lest results This was done to avoid bias by excludmg mdwidu-als who had died prematurely and therefore could not be tested. Hence, we included complete sibships in the analysis. We used the lest results to include new generations with 0.5 probability. Follow-up extended frora the date of birth to December 31,1994 or the date of death.
The causes of death could be obtained for the period 1940 to 1994. On the death certificates multiple causes are included, coded by specialized physicians of the Netherlands Central Bureau of Statistics using the International Classification of Diseases, Injuries and Causes of Death, Fifth to Ninth Revision (8, 10-13). For each death, an underlying ('primary') cause of death and any other contributing ('secondary') causes to a maximum of three are assigned (9).
We divided the causes into 7 categories: malignant neoplasms (ICD-9 codes 1400-2089), circulatory diseases (ICD-9 codes 3900-4599), cerebrovascular diseases (ICD-9 codes 4300-4389), ischemic heart diseases (ICD-9 codes 4100-4149), respiratory diseases (ICD-9 codes 4600-5199), pneumonia (ICD-9 codes 4600-4680), and thromboembolic complications. We included in the thromboembolic category the codes for "pulmonary embolism" (ICD-9 code 4151), "phlebitis and thrombophlebitis" (ICD-9 codes 4510-4519), "other venous embolism or thrombosis" (ICD-9 codes 4530-4539), "venous complications in pregnancy and puerperium" (ICD-9 codes 6710-6719), and "obstetrical pulmonary embolism" (ICD-9 codes 6730-6739) äs they are the most common venous thromboembolic complications in the general population. We assigned the ICD-codes and recoded the older ICD-codes following the Ninth Revision (8,10-13).
For the primary causes of death we obtained from the Netherlands Central Bureau of Statistics the mortality rates or annual total number of deaths from which the rates could be computed for 1940 to 1994. Population mortality rates for secondary causes have been recorded by The Netherlands Central Bureau of Statistics from 1950 onwards.
Analysis. We calculated standardized mortality ratios (SMRs) äs the ratio of the number of observed deaths in our study population to the expected number of deaths in the general population, i.e. the number of deaths that would have occurred according to the mortality rates of the general population adjusted for age, sex and calendar period. SMRs were calculated for overall mortality between 1830 and 1994; cause-specific SMRs from 1940 for underlying disorders and from 1950 for contributing disorders using the Computer program 'Person-Years' (14). The calendar periods were divided into 20-year intervals for 1830 to 1900, ten-year intervals for 1900 to 1940 and five-year intervals for 1940 to 1994. To calculate the expected number of deaths for each of these periods, we used the population mortality rates of the mid-interval year subcategorized into five year age groups and by sex.
In 2 families it could not be determined who had been the original probands and so we counted 12 probands. To eliminate bias that may have led to a falsely low SMR, we omitted person-years of the following subjects in our study cohort: probands were included only from the date of diagnosis; individuals, whose lest results were used to extend a pedigree, entered the study at the date of birth of their first child. The rationale is that, in retrospect, probands could not have died before the date of diagnosis, and persons who transmitted the gene could not have died before the age of procreation. All other individuals entered the study at the date of birth. Given the uncertainty about mortality data for children <1 year old. we omitted the first year of life of the subjects of our study cohort both for observed and expected deaths. Confidence intervals were calculated based on a Poisson distribution for the observed number of deaths (15).
Results
In 14 families, followed from 1830 to 1940,266 individuals were investigated. From their dates of entry 146 men and 120 women lived a total of 11210 person-years (all ages combined). The smallest family contributed 5 individuals to the study group and the largest, 53. In the families the number of generations varied between 2 and 6. Two families with antithrombin deficiency type II c were included, together comprising 12 individuals. A total of 11 subjects emigrated during follow-up and were censored at the emigration date.
During follow-up 86 individuals died, whereas a total of 95.9 deaths would have been expected in a hypothetical cohort of the general population with the same sex and age distribution (SMR = 0.90, 95% C.I. 0.72-1.11). Thus, from 1830 to 1994 overall mortality was not increased. The SMR for men was 0.96 (58 deaths, 95% C.I. 0.73-1.25) and for women 0.79 (28 deaths, 95% C.I. 0.53-1.15). Figure l shows the mortality rates for the various calendar periods from 1890 onwards.
From 1940 to 1994 all-cause SMR was 1.09 with no differences between men and women (44 deaths in men, SMR = 1.20; 95% C.I. 0.87-1.61; 22 deaths in women, SMR = 0.92; 95% C.I. 0.58-1.39). For this period the most frequent causes of death are listed for 58 individuals in Table l . The underlying cause of death could not be retrieved from death certificates in 8 cases: 2 subjects died in World War II; 2 died abroad and for 4 individuals we could not get hold of death certificates from the municipal records. mcluding 9 deaths from olhcr heart discascs ' mcludmg 3 deaths from chrontc respiratory diseases (SMR--I 09. 95% C l 022-3 18)
Venous thromboembolism was listed only once äs a primary cause: pulmonary embolism in puerperiurn in a 30 year old woman. Since we expected 0.31 deaths for venous thromboembolism äs primary cause, this led to a SMR of 3.23 (95% C.I. 0.08-18.00).
Most deaths (42%) were classified äs caused by circulatory diseases. This mortality was similar to that in the general population; analogously, we found no excess of cancer mortality. Mortality due to respiratory diseases was slightly higher than expected. This seemed to be due to a higher mortality of pneumonia than expected. Chronic respiratory diseases were responsible for 3 other deaths in this category.
For overall cerebrovascular diseases we found no excess mortality. This group consisted of 3 cerebral hemorrhages, occlusion of the cerebral arteries due to thrombosis in one patient, and an ill-defined vascular lesion which could have been either hemorrhagic or thrombotic of origin in one patient.
Other causes (9 deaths) included diseases of the central nervous System (3 deaths), digestive system (3 deaths), urogenital system (l death). Two deaths were classified in the category 'Symptoms, signs and ill defined conditions'. We obtained Information from the family that a fatal pulmonary embolism had been the cause of one of these two deaths, a 20 year old man without a specific acquired risk factor. In total, therefore, venous thromboembolism contributed to 2 deaths, cerebral hemorrhages to 3 deaths and occlusion of cerebral arteries to one or possibly two deaths.
To investigate whether thrombosis could have contributed to more deaths without having been listed äs the primary cause, we obtained Information of 32 secondary causes from 1950 onwards. As secondary cause we expected 1.14 deaths for venous thromboembolism but observed none (Table 2) . Circulatory diseases (15 deaths) and respiratory diseases (6 deaths) were the most frequent secondary causes. Cerebrovascular diseases äs secondary cause included 3 cases of cerebral thrombosis and embolism, l occlusion of precerebral arteries and 2 illdefined vascular lesions, which could have been either hemorrhagic or thrombotic in origin. The primary causes given in these cases were chronic nephritis (l death), cholecystitis (l death) and ischemic heart disease (4 deaths). The mean age of death (all causes) was 61 years (ränge 2-88) in men, 69 years (ränge 30-83) in women and altogether 64 years. The one thromboembolic complication in pregnancy led to the youngest death among women. In men other causes (digestive system, central nervous system) led to death at a young age. However, the fatal pulmonary embolism coded äs an "ill defined and unknown" cause of death occurred in a young man aged 20. The mean age of death from respiratory diseases was 79 years (ränge 64-88) in men and 64 years in women. For cerebrovascular diseases it was 73 years (ränge 61-85) in men and 76 years (ränge 75-77) in women. It was 82 years (ränge 80-85) for those deaths in which cerebral thrombosis contributed to mortality with circulatory diseases äs primary cause, and 58 years when it contributed to the other primary causes. For the 3 cerebral hemorrhages it was 70 years (ränge 61-75).
Discussion
Investigation of overall mortality from a follow-up from 1830 to 1994 in 14 families revealed a normal life expectancy for individuals with >0.5 probability of heterozygosity for inherited antithrombin deficiency. As this finding is not necessarily in conflict with higher mortality specifically due to venous thrombosis, we compared the cause-specific mortality in these families with that of the general population. A venous thromboembolic complication was listed only once äs the primary cause of death and was suspected in another death listed äs ''ill defined".
Although two venous thromboembolic complications is higher than expected for this cohort, it does not indicate that inherited antithrombin deficiency in these families is associated with a high rate of mortality due to thrombotic causes. Even including the total number of primary and secondary causes expected for venous thromboembolic complications (1.45 deaths), the two deaths do not immediately raise much concern. One fatal pulmonary embolism occurred during puerperiurn. In women venous thrombosis often manifests with pregnancy, puerperiurn or the use of oral contraceptives (16). However, we did not find a sex difference in overall mortality.
No large studies have investigated mortality and causes of death for inherited antithrombin deficiency before, and fatal thromboembolic episodes have been reported in some cases or pedigrees (2). Our results suggest now that those are rare occurrences, and suggest publication or detection bias in these previously published case reports or pedigree studies.
Oral anticoagulant treatment will prevent many thromboses. Longterm antithrombotic prophylaxis reduces the incidence of recurrent episodes, and when short-term prophylaxis is recommended in asymptomatic individuals in high-risk situations, a positive effect on morbidity is seen (16) (17) . As for mortality, we may conclude that no further iraprovement of survival is to be expected from long-term anticoagulation in asymptomatic individuals. Moreover, since fatalities due to thrombotic episodes remain rare, prevention of these episodes with long-term anticoagulation in asymptomatic individuals is not indicated because of the greater risk of induced fatal bleeding. Previously, we estimated this risk to be 0.6 per 100 treatment years (6).
In this study the fatal thrombotic complications, although few, were dramatic since they manifested at a young age. The postpartum death in a women aged 30 years might have been prevented by a policy of giving anticoagulation for a short period around and after delivery, which is now common practice in antithrombin deficiency. The other death, äs far äs we know, occurred outside of any risk Situation in a man aged 20 years, and therefore might only have been prevented by a policy of indiscnmmate long-term prophylaxis of asyraptomatic individuals When applymg the nsk of fatal bleedmg to the several thousand personyears, this would have led to a considerable number of hemorrhagic deaths, far outweighmg the benefits The general Impression is that artenal disease is not a feature of antithrombm deficiency, with the excepüon of homozygous type IIc deficiency where venous äs well äs artenal thrombosis may occur at a very young age (18) We found no excess mortahty for ischemic heart diseases Ischemic heart diseases are known clearly to be associated with stroke We found cerebral thrombosis and embohsm menüoned four times äs secondary cause with ischemic heart diseases In 2 more sub jects cerebral thrombosis (hsted äs a secondary cause) had contnbuted to death, at a shghtly younger age, and the pnmary cause was not ischemic heart disease One cannot exclude that similar pathogenesis ot atherosclerosis m the cerebral circulation or embohsm from left ven tncular thrombus complicatmg myocardial mfarction (undiagnosed) had existed m these 2 individuals A shghtly higher mortahty due to respiratory diseases seemed due to a higher mortality of pneumoma No mfectious orgamsms were mentioned in the 4 subjects with fatal pneumoma It cannot completely be ruled out therefore that the higher mortality m this group could be explamed by misdiagnosis of one or more underlymg pulmonary embohsms If this was the case, venous thromboembohc comphcations were somewhat underestimated However, the consequence of such an underestimate is not severe, äs the mean age of death was 75 years for these individuals
The pattern of mortahty with regard to common causes did not differ from that in the general population The companson of causes of death was based on death certificate classifications This guaranteed a valid companson äs the classification was the same for the study cohort and the general population Because we included individuals with >0 5 probabihty of bemg deficient, some individuals may, m reahty, have had normal antithrombin concentrations These normal individuals will have diluted any observed effect on mortahty, but they cannot explam that we did not find any difference in overall and specific mortahty compared to the general population
In conclusion, we found no excess mortality and no high rate of death from venous thromboembohc diseases The thrombotic fatahties that were observed developed at a relatively young age, one m association with a well known nsk Situation, but their number did not greatly exceeded the expected number for these occurrences With a greater nsk of bleedmg man the nsk of fatal thromboembohc comphcations long-term anticoagulant treatment cannot be recommended for asymptomatic individuals
